Tonix Pharmaceuticals has begun its Phase 2 OASIS trial evaluating TNX-102 SL, a potential treatment for acute stress reaction (ASR) among motor vehicle trauma survivors. The study, sponsored by the University of North Carolina's Institute for Trauma Recovery and supported by a $3 million U.S. Department of Defense grant, represents a significant step in addressing mental health challenges following traumatic events.
The trial will enroll approximately 180 participants across emergency departments nationwide, focusing on assessing the medication's effectiveness in reducing ASR severity and preventing the onset of acute stress disorder. Previous research indicates TNX-102 SL has shown promise in improving sleep and early PTSD symptoms, critical factors in managing post-traumatic stress.
Company CEO Dr. Seth Lederman emphasized the urgent need for effective interventions for both civilian and military populations experiencing acute stress. The research could potentially provide a critical therapeutic approach for individuals immediately following traumatic experiences, potentially mitigating long-term psychological consequences.
Topline data from the trial is expected in the second half of 2026, which will offer further insights into the medication's potential clinical applications. This study represents an important advancement in understanding and treating acute stress reactions, with potential broad implications for mental health treatment strategies.
